MYOS Corporation Receives Notice of Allowance of U.S. Patent Application for Proprietary Manufacturing Methods of Fortetropin


- Patent will protect MYOS' intellectual property portfolio for Fortetropin through 2033 –

- Key patent highlights the innovation underlying MYOS' novel myostatin inhibitor technology and clearly differentiates Fortetropin –

CEDAR KNOLLS, N.J., July 24, 2014 (GLOBE NEWSWIRE) -- MYOS Corporation ("MYOS" or the "Company") (Nasdaq:MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it recently received a Notice of Allowance from the U.S. Patent and Trademark Office ("USPTO") for U.S. Patent Application Serial No. 13/765,340 covering the Company's proprietary methods of manufacturing Fortetropin, the first clinically proven natural myostatin inhibitor. Upon issuance, the U.S. Patent entitled, "Process for Producing a Composition Containing Active Follistatin," will provide intellectual property protection for making the key ingredient in MYOS' core commercial muscle health products and carries a patent term through early 2033.

"This patent allowance is a significant achievement for MYOS. Patent protection is of the upmost importance as we advance our development and commercialization strategy based on Fortetropin, the primary component in our bionutrition supplement products, as well as future biotherapeutic brands we envision," commented Peter Levy, President and Chief Operating Officer of MYOS. "A critical element to our success is the ability to protect and maintain our proprietary rights in order to achieve the best outcome for revenue generation and shareholder return.  The issuance of the Fortetropin manufacturing patent will enable us to rigorously defend the integrity of our intellectual property portfolio."

The USPTO issues a Notice of Allowance after it makes a determination that a claimed invention is novel and nonobvious in light of all known technology in existence, and that a patent should be granted from such an application. Based on the timing of this Notice of Allowance, MYOS expects the forthcoming Fortetropin patent to be issued by the end of the third quarter of 2014.

Robert Ashton, M.D., Chief Medical Officer of MYOS added, "The issuance of this patent related to our proprietary methodology to manufacture Fortetropin will strengthen our IP portfolio. This key patent highlights the innovation necessary to create MYOS' novel myostatin inhibitor technology.  The combination of the core components and the process needed to formulate Fortetropin are unique and differentiate it from competitive products targeting muscle health."

Mr. Levy concluded, "Upon issuance of the patent, MYOS will be the only company in the bionutrition, biotherapeutics and medical food space with the ability to produce, sell, offer for sale or import our core formulation specifically designed and manufactured using the proprietary methodology covered by our the patent.  We believe that, as the sole owner of all Fortetropin-based formulations, MYOS will have a unique competitive advantage as the leader in the field of muscle health."

About MYOS Corporation

MYOS is a developmental stage biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin (MYO-T12®), the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS is known as "The Muscle Company," visit

The Company's first commercial product based on Fortetropin (MYO-T12), is distributed by Maximum Human Performance (MHP) under the brand name MYO-X® and is currently available on popular retailer websites including,, and in specialty retailers including GNC and Vitamin Shoppe and others. MYOS believes that Fortetropin, as well as future products it envisions, will redefine existing standards for muscle health.

Forward-Looking Statements

Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin (MYO-T12®) and its effects on myostatin inhibition, including our research and development activities, product and customer demand, the continued growth of repeat purchases, market acceptance of our existing and future products, the ability to create new products through research and development, the successful completion of the research program with Cloud Pharmaceuticals described herein and the expansion of our biotherapeutic development pipeline, the continued growth in market expansion and revenue including the expansion into the age management market, the successful entry into new markets including the age management market, the ability to attract additional investors and increase shareholder value, the ability to generate the forecasted revenue stream and cash flow from sales of Fortetropin and MYO-X®, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights including the notice of allowance for a patent described herein as well as the issuance of such patent by the USPTO, the continued growth and expansion of MYO-X in GNC, Vitamin Shoppe and other specialty retail stores, the ability to strengthen our manufacturing relationships and reduce the costs of our products, the ability to comply with NASDAQ's continuing listing standards, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.


Contact Data